- Home
- NGD vs PTGX Comparison
NGD vs PTGX Comparison
Compare NGD & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGD
- PTGX
- Stock Information
- Founded
- NGD N/A
- PTGX 2006
- Country
- NGD Canada
- PTGX United States
- Employees
- NGD N/A
- PTGX N/A
- Industry
- NGD
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- NGD
- PTGX Health Care
- Exchange
- NGD Nasdaq
- PTGX Nasdaq
- Market Cap
- NGD 3.9B
- PTGX 3.3B
- IPO Year
- NGD 2004
- PTGX 2016
- Fundamental
- Price
- NGD $5.21
- PTGX $55.78
- Analyst Decision
- NGD Buy
- PTGX Strong Buy
- Analyst Count
- NGD 2
- PTGX 8
- Target Price
- NGD $5.50
- PTGX $70.13
- AVG Volume (30 Days)
- NGD 14.6M
- PTGX 633.4K
- Earning Date
- NGD 07-28-2025
- PTGX 08-06-2025
- Dividend Yield
- NGD N/A
- PTGX N/A
- EPS Growth
- NGD N/A
- PTGX N/A
- EPS
- NGD 0.18
- PTGX 0.80
- Revenue
- NGD $1,031,700,000.00
- PTGX $209,180,000.00
- Revenue This Year
- NGD $47.11
- PTGX N/A
- Revenue Next Year
- NGD $44.56
- PTGX $53.09
- P/E Ratio
- NGD $27.83
- PTGX $68.40
- Revenue Growth
- NGD 27.25
- PTGX N/A
- 52 Week Low
- NGD $2.31
- PTGX $33.31
- 52 Week High
- NGD $5.17
- PTGX $60.60
- Technical
- Relative Strength Index (RSI)
- NGD 67.91
- PTGX 53.03
- Support Level
- NGD $4.71
- PTGX $50.49
- Resistance Level
- NGD $5.17
- PTGX $56.85
- Average True Range (ATR)
- NGD 0.16
- PTGX 2.05
- MACD
- NGD 0.08
- PTGX 0.08
- Stochastic Oscillator
- NGD 91.45
- PTGX 64.04
About NGD New Gold Inc.
New Gold Inc participates in the development and operation of intermediate mining properties. The company has a portfolio of two primary assets which are also its operating segments: the Rainy River Mine and the New Afton Mine in Canada. The company also owns the Cerro San Pedro Mine in Mexico. The company derives revenue from the sale of gold, copper, and silver.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.